Overview: Influenza Antigen Rapid TestIntroduction: The Influenza Antigen Rapid Test is a diagnostic tool designed to detect influenza antigens in nasopharyngeal, nasal swabs, or saliva samples, facilitating the screening of influenza. Caused by influenza A or B viruses, this respiratory infection presents with fever, cough, and severe complications like pneumonia or respiratory failure if untreated, particularly in the elderly or immunocompromised. Per the 2023 Centers for Disease Control and Prevention guidelines, the test employs immunochromatographic technology, delivering results within 15-20 minutes with high sensitivity and specificity, making it a critical tool for rapid diagnosis during flu seasons. This rapid diagnostic falls under virology and targets individuals with respiratory symptoms, addressing the challenge of distinguishing influenza from other respiratory viruses to guide antiviral therapy with oseltamivir or zanamivir. With morbidity rates elevated due to seasonal epidemics, the test supports public health efforts by enabling early detection, facilitating isolation, and promoting vaccination campaigns. Its multi-sample capability enhances its utility in diverse settings.Other Names: Influenza Rapid Test.FDA Status: FDA approved, CLIA certified for virology, compliant with 2025 standards.Historical Milestone: Introduced in the 2000s by Quidel, this test advanced influenza detection, providing a rapid alternative to viral culture.Purpose: The test screens for influenza antigens to guide infection diagnosis, assess disease severity, and inform treatment and prevention strategies.Test Parameters: Presence of Influenza Antigen, detected with high specificity to indicate active infection, typically detectable during the acute phase, peaking within 2-4 days of symptom onset.Pretest Condition: No fasting required; patients should avoid food or drink for 30 minutes prior to collection to ensure sample integrity, and they should report fever, cough, or recent flu exposure.Specimen: Nasopharyngeal Swab 1-2 swabs, Nasal Swab 1-2 swabs, Saliva 1-2 mL, collected using sterile swabs/transport medium or containers, transported within 24 hours to maintain sample viability.Sample Stability at Room Temperature: 24 hours with proper handling in a cool environment to preserve antigen integrity, ensuring reliable test performance.Sample Stability at Refrigeration: 48 hours at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.Sample Stability at Frozen: Not recommended, as freezing may denature antigens, increasing the risk of false negatives and compromising diagnostic accuracy.Medical History: Patients should provide details on fever, cough, respiratory symptoms, or prior influenza infections, as well as any immunosuppressive conditions or vaccination status.Consent: Written informed consent is required, detailing the test's purpose, potential risks of untreated infection including pneumonia, benefits of early detection, and minimal discomfort from sample collection.Procedural Considerations: The test utilizes an immunochromatographic cassette requiring trained personnel to ensure sterile technique, avoid contamination, and interpret results within 15-20 minutes using provided positive and negative controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols, and store test kits according to manufacturer specifications to ensure reliability.Factors Affecting Result Accuracy: Delays beyond 24 hours, improper storage conditions, cross-contamination with other samples, or late infection after antigen clearance can affect results. Correlation with PCR or viral culture is recommended to confirm findings.Clinical Significance: A positive result indicates influenza infection, necessitating antiviral therapy and isolation. A negative result may require follow-up testing if symptoms persist, especially if sampled outside the antigen peak window.Specialist Consultation: Infectious disease specialists or pulmonologists should be consulted for case management, treatment planning, and coordination with public health authorities.Additional Supporting Tests: Influenza PCR, viral culture, or serology for confirmation.Test Limitations: The test may produce false negatives in late infection or false positives due to cross-reactivity, requiring a comprehensive diagnostic approach that includes molecular methods.References: CDC Guidelines 2023, Journal of Clinical Virology 2024, Respiratory Medicine 2025.